ArticleStem cell research & therapy2017
Term amniotic fluid: an unexploited reserve of mesenchymal stromal cells for reprogramming and potential cell therapy applications.
Article in Stem cell research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Amniotic fluid collected from vaginal birth as a source of stem cells for clinical applications and disease modeling.Stem cells translational medicine · 2025Article
- hUC-MSC extracellular vesicles protect against hypoxic-ischemic brain injury by promoting NLRP3 ubiquitination.Biomolecules & biomedicine · 2025Article
- Article
- Review
- Development of a new treatment for preterm birth complications using amniotic fluid stem cell therapy.Histology and histopathology · 2023Review
- Multipotent fetal stem cells in reproductive biology research.Stem cell research & therapy · 2023Review
- Human Mesenchymal Stromal Cells Derived from Perinatal Tissues: Sources, Characteristics and Isolation Methods.The Malaysian journal of medical sciences : MJMS · 2023Review
- Mesenchymal stromal cell-based therapy for cartilage regeneration in knee osteoarthritis.Stem cell research & therapy · 2022Review
- Significance of Placental Mesenchymal Stem Cell in Placenta Development and Implications for Preeclampsia.Frontiers in pharmacology · 2022Review
- Review
- Novel cell sources for bone regeneration.MedComm · 2021Review
- Human Mesenchymal Stromal Cells Are Resistant to SARS-CoV-2 Infection under Steady-State, Inflammatory Conditions and in the Presence of SARS-CoV-2-Infected Cells.Stem cell reports · 2021Article
- Amniotic fluid-derived multipotent stromal cells drive diabetic wound healing through modulation of macrophages.Journal of translational medicine · 2021Article
- Review
- Adult mesenchymal stem cells: is there a role for purine receptors in their osteogenic differentiation?Purinergic signalling · 2020Review
- Different culture method changing CD105 expression in amniotic fluid MSCs without affecting differentiation ability or immune function.Journal of cellular and molecular medicine · 2020Article
- Placental mesenchymal stromal cells as an alternative tool for therapeutic angiogenesis.Cellular and molecular life sciences : CMLS · 2020Review
- Amniotic Fluid Stem Cells for the Treatment of Surgical Disorders in the Fetus and Neonate.Stem cells translational medicine · 2018Article
- The Impact of Epigenetic Signatures on Amniotic Fluid Stem Cell Fate.Stem cells international · 2018Review
- Differentiation of CD117Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesenchymal stromal cells (MSCs) are currently being evaluated in numerous pre-clinical and clinical cell-based therapy studies. Furthermore, there is an increasing interest in exploring alternative uses of these cells in disease modelling, pharmaceutical screening, and regenerative medicine by applying reprogramming technologies. However, the limited availability of MSCs from various sources restricts their use. Term amniotic fluid has been proposed as an alternative source of MSCs. Previously, only low volumes of term fluid and its cellular constituents have been collected, and current knowledge of the MSCs derived from this fluid is limited. In this study, we collected amniotic fluid at term using a novel collection system and evaluated amniotic fluid MSC content and their characteristics, including their feasibility to undergo cellular reprogramming.
methodsAmniotic fluid was collected at term caesarean section deliveries using a closed catheter-based system. Following fluid processing, amniotic fluid was assessed for cellularity, MSC frequency, in-vitro proliferation, surface phenotype, differentiation, and gene expression characteristics. Cells were also reprogrammed to the pluripotent stem cell state and differentiated towards neural and haematopoietic lineages.
resultsThe average volume of term amniotic fluid collected was approximately 0.4 litres per donor, containing an average of 7 million viable mononuclear cells per litre, and a CFU-F content of 15 per 100,000 MNCs. Expanded CFU-F cultures showed similar surface phenotype, differentiation potential, and gene expression characteristics to MSCs isolated from traditional sources, and showed extensive expansion potential and rapid doubling times. Given the high proliferation rates of these neonatal source cells, we assessed them in a reprogramming application, where the derived induced pluripotent stem cells showed multigerm layer lineage differentiation potential.
conclusionsThe potentially large donor base from caesarean section deliveries, the high yield of term amniotic fluid MSCs obtainable, the properties of the MSCs identified, and the suitability of the cells to be reprogrammed into the pluripotent state demonstrated these cells to be a promising and plentiful resource for further evaluation in bio-banking, cell therapy, disease modelling, and regenerative medicine applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.